{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T09:27:36Z","timestamp":1793698056285,"version":"4.5.1"},"reference-count":47,"publisher":"The Journal of Rheumatology","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2026,5,20]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Little is known as to whether the American College of Rheumatology\/European Alliance of Associations for Rheumatology Total Improvement Score (TIS) reflects how patients with autoimmune inflammatory myopathies (AIM) feel and function. We assessed the associations between TIS and changes in the scores of a wide range of patient-reported outcomes (PROs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adult patients with AIM and active disease at baseline who completed a 1-year follow-up visit were identified from a research cohort. PROs included a numerical rating scale for pain, the Functional Assessment of Chronic Illness Therapy \u2013 Fatigue (FACIT-Fatigue) scale, the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v1.0 Fatigue 8a, the 9-item Patient Health Questionnaire (PHQ-9), and the 36-Item Short Form Health Survey (SF-36) physical and mental component summary scores (PCS and MCS, respectively). Multivariable linear regression models were generated to determine the absolute change in PRO scores for each 20-unit increase in absolute TIS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 65 patients with active disease for whom TIS could be calculated. At 1 year, 40% showed no improvement, 34% achieved minimal improvement, and 26% achieved moderate improvement. In adjusted models, increase in absolute TIS was associated with statistically significant improvements in pain, PROMIS-Fatigue, FACIT-Fatigue, and SF-36 PCS scores. For FACIT-Fatigue, a significant interaction was identified between age and TIS. In stratified analyses, only patients with shorter disease duration significantly improved in pain and FACIT-Fatigue scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The findings of this cohort study support the use of the TIS in AIM research but also highlight potential limitations in its ability to capture outcomes across the broader AIM spectrum, particularly among older individuals and those with longer disease duration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2026-0046","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:20:12Z","timestamp":1781526012000},"page":"1002-1012","source":"Crossref","is-referenced-by-count":0,"title":["Does the ACR\/EULAR Total Improvement Score Reflect How Individuals With Autoimmune Inflammatory Myopathies Feel and Function?"],"prefix":"10.3899","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8643-6697","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Leclair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5499-2661","authenticated-orcid":false,"given":"Claudie","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7246-9428","authenticated-orcid":false,"given":"Maude","family":"Bouchard-Marmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josiane","family":"Bourr\u00e9-Tessier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oc\u00e9ane","family":"Landon-Cardinal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Canadian Inflammatory Myopathy Study","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6718-2468","authenticated-orcid":false,"given":"Marie","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"2026110300451241000_53.9.1002.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211468"},{"key":"2026110300451241000_53.9.1002.2","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12380"},{"key":"2026110300451241000_53.9.1002.3","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000173991.74008.b0"},{"key":"2026110300451241000_53.9.1002.4","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410380504"},{"key":"2026110300451241000_53.9.1002.5","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"key":"2026110300451241000_53.9.1002.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.20349"},{"key":"2026110300451241000_53.9.1002.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211400"},{"key":"2026110300451241000_53.9.1002.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117912"},{"key":"2026110300451241000_53.9.1002.9","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026110300451241000_53.9.1002.10","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/acr2.11493","article-title":"Randomized trial of tocilizumab in the treatment of refractory adult polymyositis and dermatomyositis","volume":"4","author":"Oddis","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"2026110300451241000_53.9.1002.11","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/rheumatology\/kead281","article-title":"Belimumab treatment of adult idiopathic inflammatory myopathy","volume":"63","author":"Marder","year":"2023","journal-title":"Rheumatology"},{"key":"2026110300451241000_53.9.1002.12","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/rheumatology\/keae143","article-title":"A patient centered assessment of the 2016 ACR-EULAR Myositis Response Criteria: evaluating the meaningfulness of response","volume":"64","author":"Saygin","year":"2025","journal-title":"Rheumatology"},{"key":"2026110300451241000_53.9.1002.13","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000837"},{"key":"2026110300451241000_53.9.1002.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2008.10.013"},{"key":"2026110300451241000_53.9.1002.15","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181412"},{"key":"2026110300451241000_53.9.1002.16","first-page":"279","article-title":"Health-related quality of life improvements and response thresholds of myositis outcome measures and response criteria","volume":"44","author":"Almackenzie","year":"2026","journal-title":"Clin Exp Rheumatol"},{"key":"2026110300451241000_53.9.1002.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.21291"},{"key":"2026110300451241000_53.9.1002.18","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0180"},{"key":"2026110300451241000_53.9.1002.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.34473"},{"key":"2026110300451241000_53.9.1002.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204424"},{"key":"2026110300451241000_53.9.1002.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"2026110300451241000_53.9.1002.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210571"},{"key":"2026110300451241000_53.9.1002.23","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/rheumatology\/keab492","article-title":"Autoantibody profiles delineate distinct subsets of scleromyositis","volume":"61","author":"Leclair","year":"2022","journal-title":"Rheumatology"},{"key":"2026110300451241000_53.9.1002.24","doi-asserted-by":"crossref","first-page":"e12840","DOI":"10.1111\/nan.12840","article-title":"Capillary pathology with prominent basement membrane reduplication is the hallmark histopathological feature of scleromyositis","volume":"48","author":"Ellezam","year":"2022","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2026110300451241000_53.9.1002.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.09.016"},{"key":"2026110300451241000_53.9.1002.26","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21583"},{"key":"2026110300451241000_53.9.1002.27","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/art.40064","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an international myositis assessment and clinical studies group\/paediatric rheumatology international trials organisation collaborative initiative","volume":"69","author":"Aggarwal","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026110300451241000_53.9.1002.28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s41687-019-0115-4","article-title":"Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis","volume":"3","author":"Cella","year":"2019","journal-title":"J Patient Rep Outcomes"},{"key":"2026110300451241000_53.9.1002.29","doi-asserted-by":"crossref","first-page":"104048","DOI":"10.1016\/j.msard.2022.104048","article-title":"A comparison of the measurement properties of the PROMIS Fatigue (MS) 8a against legacy fatigue questionnaires","volume":"66","author":"Kamudoni","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"2026110300451241000_53.9.1002.30","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2019-000373"},{"key":"2026110300451241000_53.9.1002.31","doi-asserted-by":"publisher","DOI":"10.1097\/NNR.0000000000000162.Psychometric"},{"key":"2026110300451241000_53.9.1002.32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s41687-019-0105-6","article-title":"PROMIS Fatigue short forms are reliable and valid in adults with rheumatoid arthritis","volume":"3","author":"Bingham","year":"2019","journal-title":"J Patient Rep Outcomes"},{"key":"2026110300451241000_53.9.1002.33","doi-asserted-by":"crossref","first-page":"152534","DOI":"10.1016\/j.semarthrit.2024.152534","article-title":"Construct validity of PROMIS pain interference, fatigue, and physical function as patient-reported outcomes in adults with idiopathic inflammatory myopathies: an international study from the OMERACT myositis working group","volume":"68","author":"Romich","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2026110300451241000_53.9.1002.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152111"},{"key":"2026110300451241000_53.9.1002.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2007.06.004"},{"key":"2026110300451241000_53.9.1002.36","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20532"},{"key":"2026110300451241000_53.9.1002.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2018.05.007"},{"key":"2026110300451241000_53.9.1002.38","first-page":"234","article-title":"Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials","volume":"14","author":"Strand","year":"2008","journal-title":"Am J Manag Care"},{"key":"2026110300451241000_53.9.1002.39","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12874-016-0167-6","article-title":"Minimal important differences for fatigue patient reported outcome measures\u2014a systematic review","volume":"16","author":"Nordin","year":"2016","journal-title":"BMC Med Res Methodol"},{"key":"2026110300451241000_53.9.1002.40","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291720003700"},{"key":"2026110300451241000_53.9.1002.41","doi-asserted-by":"crossref","first-page":"152339","DOI":"10.1016\/j.semarthrit.2023.152339","article-title":"Responsiveness and meaningful thresholds of PROMIS pain interference, fatigue, and physical function forms in adults with idiopathic inflammatory myopathies: report from the OMERACT Myositis Working Group","volume":"64","author":"Saygin","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2026110300451241000_53.9.1002.42","unstructured":"US Food and Drug Administration . FDA patient-focused drug development guidance series for enhancing the incorporation of the patient\u2019s voice in medical product development and regulatory decision making 2019. [Internet. Accessed May 11, 2023.] Available from: https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical"},{"key":"2026110300451241000_53.9.1002.43","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181065"},{"key":"2026110300451241000_53.9.1002.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.08.001"},{"key":"2026110300451241000_53.9.1002.45","doi-asserted-by":"crossref","first-page":"974078","DOI":"10.3389\/fimmu.2022.974078","article-title":"Scleromyositis: A distinct novel entity within the systemic sclerosis and autoimmune myositis spectrum. Implications for care and pathogenesis","volume":"13","author":"Giannini","year":"2023","journal-title":"Front Immunol"},{"key":"2026110300451241000_53.9.1002.46","doi-asserted-by":"crossref","first-page":"100337","DOI":"10.1016\/j.xjidi.2024.100337","article-title":"Development and evaluation of the dermatomyositis outcomes for muscle and skin as an outcome measure in dermatomyositis clinical trials","volume":"5","author":"Pandya","year":"2025","journal-title":"JID Innov"},{"key":"2026110300451241000_53.9.1002.47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503531"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2026-0046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:46:33Z","timestamp":1793695593000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2026-0046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":47,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,1]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.3899\/jrheum.2026-0046"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2026-0046","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]}}}